![](/wp-content/uploads/2022/03/March-21-2022-Cover.png)
$599
Teplizumab BLA Re-submission Accepted by FDA; March 21-24 CHMP Agenda
Two cardiometabolic-related news items have been observed: Provention Bio announced FDA has accepted the resubmitted teplizumab BLA for the delayed onset of T1DM; and the CHMP agenda for this month’s meeting (March 21-24) has been released. Below, FENIX provides highlights and insights for the respective new items.